Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29608734 | 1.00 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL18207479 | 1.00 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL19945796 | 1.00 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL18207299 | 0.93 | TLR7 (1.00) | TLR7 | |
| SCHEMBL19974084 | 0.91 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL29488798 | 0.91 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL19945292 | 0.91 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL29608621 | 0.91 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL18207274 | 0.91 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL18207406 | 0.91 | TLR7 (1.00) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11337982-B2 | Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor | HOFFMANN-LA ROCHE, INC. (US) | 2022-05-24 | — | — | US | claimed |
| EP-3512556-B1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | HOFFMANN LA ROCHE (CH) | 2021-08-18 | — | — | EP | claimed |
| US-20190298726-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | HOFFMANN-LA ROCHE INC. (US) | 2019-10-03 | — | — | US | claimed |
| EP-3512556-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | H. Hoffnabb-La Roche Ag (CH) | 2019-07-24 | — | — | EP | claimed |
| WO-2018050571-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-22 | — | — | WO | claimed |
| US-11337982-B2 | Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor | HOFFMANN-LA ROCHE, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3970750-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | F. Hoffmann-La Roche AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| EP-3512556-B1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | HOFFMANN LA ROCHE (CH) | 2021-08-18 | — | — | EP | disclosed |
| US-20190298726-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | HOFFMANN-LA ROCHE INC. (US) | 2019-10-03 | — | — | US | disclosed |
| EP-3512556-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | H. Hoffnabb-La Roche Ag (CH) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050571-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298726-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | TLR7, TLR9, HAVCR2 | TLR7 1/4885TLR8 9/4885 |
| US-11337982-B2 | Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor | TLR7, TLR9, HAVCR2 | TLR7 1/4885TLR8 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.